Sekisui Chemical Of Japan To Increase Overseas Diagnostic Agent Sales
This article was originally published in PharmAsia News
Executive SummarySekisui Chemical plans to increase overseas diagnostic agent sales from its current 20 percent to 30 percent in 2013. Last year, the top Japanese diagnostic maker acquired U.S. companies Xenotech and American Diagnostics. Sekisui plans to expand Xenotech's pharmacokinetics business and ADI's DVV line of diagnostic tests, which detect specific antibodies related to conditions associated with lupus anticoagulants. Five core areas identified by the company are: LDL/HDL testing agents, anticoagulants, diabetes, infection and advanced technology. (Click here for more - Japanese Language
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.